Login to Your Account



Biogen and Ionis 'CHERISH' phase III nusinersen findings

By Marie Powers
News Editor

Monday, November 7, 2016

Biogen Inc. looked for a broader label in connection with potential approval of the SMA candidate, nusinersen, after reporting with Ionis Pharmaceuticals Inc. that the phase III CHERISH trial in children with later-onset disease met the primary endpoint early.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription